公开(公告)号：USRE40831E1

公开(公告)日：2009-07-07

申请号：US10423036

申请日：1997-06-10

Applicant: Yair Reisner ,  Shlomo Dagan

Inventor： Yair Reisner ,  Shlomo Dagan

IPC: C07K16/08

CPC classification number: A01K67/0271 ,  A61K38/00 ,  A61K39/00 ,  C07K16/082

Abstract: Disclosed is a process for obtaining hybridoma cell lines which produce human antibodies capable of binding to the hepatitis B virus surface antigen (HBVsAg), as well as the hybridoma cell lines, and antibodies produced by the cell lines. Also disclosed are various uses of said antibodies in the prevention and treatment of HBV infection. Peripheral blood lymphocytes obtained from human donors having a high titer of anti HBVsAg antibodies are engrafted into normal strains of mice which were lethally irradiated and radioprotected with SCID bone marrow. After immunization of such chimeric mice with HBVsAg, human cells are obtained from the mice spleens and fused in vitro with heteromyeloma cells to generate hybridomas secreting human antibodies having a high affinity and specificity to HBVsAg.

Abstract translation: 公开了一种获得能够结合乙型肝炎病毒表面抗原（HBVsAg）的人抗体以及杂交瘤细胞系和由细胞系产生的抗体的杂交瘤细胞系的方法。 还公开了所述抗体在预防和治疗HBV感染中的各种用途。 从具有高滴度的抗HBVsAg抗体的人供体获得的外周血淋巴细胞被移植到正常的小鼠细胞中，其被致死性照射并用SCID骨髓放射防护。 用HBVsAg免疫这样的嵌合小鼠后，从小鼠脾获得人细胞，并与异源骨髓瘤细胞体外融合以产生分泌具有高亲和性和对HBVsAg特异性的人抗体的杂交瘤。

公开(公告)号：US20090155288A1

公开(公告)日：2009-06-18

申请号：US12320207

申请日：2009-01-21

Applicant: Yosef Yarden ,  Michael Sela

Inventor： Yosef Yarden ,  Michael Sela

IPC: A61K39/395 ,  A61P35/00

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/73 ,  C07K2317/77 ,  C07K2319/30

Abstract: A method of identifying a combination of antibodies with a combined improved anti tumor activity is provided. The method comprising identifying at least two anti RTK antibodies capable of inducing synergistic endocytosis of the RTK in a cell expressing the RTK, thereby identifying the combination of antibodies with the combined improved anti-tumor activity.

Abstract translation: 提供了鉴定抗体组合与组合改善的抗肿瘤活性的方法。 该方法包括鉴定在表达RTK的细胞中能够诱导RTK的协同内吞作用的至少两种抗RTK抗体，从而鉴定抗体与组合的改善的抗肿瘤活性的组合。

公开(公告)号：US20090137999A1

公开(公告)日：2009-05-28

申请号：US12363793

申请日：2009-02-02

Applicant: Yaron SILBERBERG ,  Dvir Yelin ,  Dan Oron

Inventor： Yaron SILBERBERG ,  Dvir Yelin ,  Dan Oron

IPC: A61B18/18

CPC classification number: A61B18/22 ,  A61B18/1482 ,  A61B18/20 ,  A61B2018/00982

Abstract: Method and apparatus for the ionization of living cells where an optical device (14) delivers an optical pulse having an optical field power which is modified locally by an optical field power modifying means (18) to effect ionization and destruction of living cells (16).

Abstract translation: 用于使细胞电离的方法和装置，其中光学装置（14）递送具有光场功率的光脉冲，该光脉冲由光场功率调节装置（18）局部修改以实现活细胞（16）的电离和破坏， 。

公开(公告)号：US20090136462A1

公开(公告)日：2009-05-28

申请号：US12326675

申请日：2008-12-02

Applicant: Lea EISENBACH ,  Erez Bar-Haim ,  Adrian Paz ,  Matityahu Fridkin ,  Cheryl Fitzer-Attas

Inventor： Lea EISENBACH ,  Erez Bar-Haim ,  Adrian Paz ,  Matityahu Fridkin ,  Cheryl Fitzer-Attas

IPC: A61K35/12 ,  C07K7/06 ,  A61K38/08

CPC classification number: C12N9/6445 ,  A61K39/00 ,  A61K48/00 ,  C07K14/47 ,  C07K14/4727 ,  C07K14/705 ,  C12N9/16

Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.

Abstract translation: 本发明涉及肿瘤相关抗原（TAA）肽及其使用方法，其编码相同的多核苷酸和与抗肿瘤疫苗相同的细胞。 更具体地说，本发明涉及衍生自Uroplatinin Ia，Ib，II和III，前列腺特异性抗原（PSA），前列腺酸性磷酸酶（PAP）和前列腺特异性膜抗原（PSMA），BA-46（Lactadherin ），粘蛋白（MUC-1）和细胞因子来源的生长因子（CRIPTO-1），以及其与抗肿瘤疫苗的用途预防或治愈膀胱，前列腺，乳腺癌或其他癌症，特别是癌症。 最特别地，本发明涉及可由HLA-A2分子呈递给免疫系统的肿瘤相关抗原肽。

公开(公告)号：US20090130121A1

公开(公告)日：2009-05-21

申请号：US11883734

申请日：2006-02-02

Applicant: Ruth Arnon ,  Arkady-Avi Kotlyar ,  Aviv Shayish ,  Dror Haratz

Inventor： Ruth Arnon ,  Arkady-Avi Kotlyar ,  Aviv Shayish ,  Dror Haratz

IPC: A61K38/00 ,  A61K38/07 ,  A61K38/06 ,  A61K38/10 ,  A61K39/395 ,  A61P9/00

CPC classification number: C12N15/1136 ,  A61K31/785 ,  A61K38/02 ,  C12N15/111 ,  C12N2320/31 ,  A61K2300/00

Abstract: The present invention relates to the use of random or ordered copolymers including the known copolymer glatiramer (also known as Copolymer 1) and Copolymer 1-related heteropolymers or ordered peptides, for treating or preventing cardiovascular diseases and disorders.

Abstract translation: 本发明涉及随机或有序共聚物的用途，包括已知的共聚物格拉美姆（也称为共聚物1）和共聚物1相关的杂多聚物或有序肽，用于治疗或预防心血管疾病和病症。

公开(公告)号：US20090124564A1

公开(公告)日：2009-05-14

申请号：US11794783

申请日：2006-01-05

Applicant: Atan Gross ,  Michal Grinberg ,  Yehudit Zaltsman

Inventor： Atan Gross ,  Michal Grinberg ,  Yehudit Zaltsman

IPC: A61K31/7052 ,  C12N5/00 ,  A01K67/033 ,  A61P35/00 ,  A61P37/02 ,  A61P25/00

CPC classification number: C07K16/18 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  A61K38/1709 ,  C07K14/4747 ,  C12N15/8509 ,  C12N2799/022

Abstract: Methods and pharmaceutical compositions for regulating apoptosis and treating pathologies associated with disregulated apoptosis are provided. Specifically the present invention provides agents capable of modulating the expression of an MCD-containing protein (e.g., Mtch2) capable of tBID binding activity and/or the tBID binding activity of the MCD-containing protein.

Abstract translation: 提供了调节细胞凋亡和治疗与细胞凋亡相关的病理学的方法和药物组合物。 具体地说，本发明提供了能够调节含有MCD的蛋白质的具有tBID结合活性和/或tBID结合活性的含有MCD的蛋白质（例如，Mtch2）的表达的试剂。

公开(公告)号：US07524928B2

公开(公告)日：2009-04-28

申请号：US11350094

申请日：2006-02-09

Applicant: Michel Revel ,  Carolina Abramovitch ,  Judith E. Chebath

Inventor： Michel Revel ,  Carolina Abramovitch ,  Judith E. Chebath

IPC: C07K14/00

CPC classification number: C12N9/1007 ,  A61K38/21 ,  C07K14/4702 ,  C07K14/555 ,  A61K2300/00

Abstract: Novel proteins IR1B1 and IR1B4 have been isolated which bind to the type I IFN receptor IFNAR1 and function in the cellular response to IFNs. DNA encoding such proteins in either the sense or anti-sense orientation can be administered to either enhance or inhibit the cellular response to IFNs. Antibodies to the proteins can be used for isolation of the new protein or for immunodetection thereof.

Abstract translation: 已经分离出新的蛋白质IR1B1和IR1B4，其结合I型IFN受体IFNAR1并在细胞对IFN的反应中起作用。 可以施用编码有义或反义方向的蛋白质的DNA，以增强或抑制对IFN的细胞应答。 蛋白质的抗体可用于分离新蛋白质或用于免疫检测。

公开(公告)号：US07514086B2

公开(公告)日：2009-04-07

申请号：US11672429

申请日：2007-02-07

Applicant: Ruth Arnon ,  Tamar Ben-Yedidia ,  Raphael Levi

Inventor： Ruth Arnon ,  Tamar Ben-Yedidia ,  Raphael Levi

IPC: A61K39/145

CPC classification number: C12N7/00 ,  A61K39/12 ,  A61K39/145 ,  A61K39/385 ,  A61K2039/543 ,  A61K2039/58 ,  A61K2039/6068 ,  C12N2760/16134

Abstract: A human synthetic peptide-based influenza vaccine for intranasal administration comprises a mixture of flagella containing at least four epitopes of influenza virus reactive with human cells, each expressed individually in Salmonella flagellin, said influenza virus epitopes being selected from the group consisting of: (i) one B-cell hemagglutinin (HA) epitope; (ii) one T-helper hemagglutinin (HA) or nucleo-protein (NP) epitope that can bind to many HLA molecules; and (iii) at least two cytotoxic lymphocyte (CTL) nucleoprotein (NP) or matrix protein (M) epitopes that are restricted to the most prevalent HLA molecules in different human populations.

Abstract translation: 用于鼻内给药的基于人的基于合成肽的流感疫苗包含含有至少四种与人类细胞反应的流感病毒表位的鞭毛的混合物，每种表达单独在沙门氏菌鞭毛蛋白中表达，所述流感病毒表位选自：（i ）一个B细胞血凝素（HA）表位; （ii）可以结合许多HLA分子的一种T辅助血凝素（HA）或核蛋白（NP）表位; 和（iii）限于不同人群中最流行的HLA分子的至少两种细胞毒性淋巴细胞（CTL）核蛋白（NP）或基质蛋白（M）表位。

公开(公告)号：US20090058428A1

公开(公告)日：2009-03-05

申请号：US12289525

申请日：2008-10-29

Applicant: Ziv Reich ,  Dan Shahar ,  Ruti Kapon

Inventor： Ziv Reich ,  Dan Shahar ,  Ruti Kapon

IPC: G01N27/22 ,  H01G9/004 ,  F17D1/00

CPC classification number: G01N33/48707 ,  Y10T29/49002 ,  Y10T137/0324 ,  Y10T137/8593

Abstract: A device for monitoring dripping of a fluid from a fluid channel, the device comprises a capacitor, being formed on or integrated with the fluid channel, and electrical contacts, connecting the capacitor to a capacitance measuring device, the capacitor is designed and constructed so that a change in a capacitance thereof represents a formation of a drop near an edge of the fluid channel.

公开(公告)号：US07488991B2

公开(公告)日：2009-02-10

申请号：US11292370

申请日：2005-12-02

Applicant: David Cahen ,  Igor Lubomirsky

Inventor： David Cahen ,  Igor Lubomirsky

IPC: H01L29/74

CPC classification number: G01N27/4143 ,  H01L2924/0002 ,  H01L2924/00

Abstract: A semiconductor sensing device for sensing presence, absence or level of species-of-interest in the environment is disclosed. The semiconductor sensing device comprises at least one layer of molecules deposited thereon. The molecules are electrically-responsive to the species-of-interest in a manner such that when the molecules interact with the species-of-interest, a reverse breakdown voltage characterizing the semiconductor sensing device is modified.

Abstract translation: 公开了一种用于感测环境中感兴趣的物体的存在，不存在或水平的半导体感测装置。 半导体感测装置包括沉积在其上的至少一层分子。 分子对感兴趣的物种具有电响应，使得当分子与感兴趣的物质相互作用时，改变表征半导体感测装置的反向击穿电压。